Article
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Annals of hematology - 1 Jan 2016
Ahn Jae-Sook, Kim Jae-Young, Kim Hyeoung-Joon, Kim Yeo-Kyeoung, Lee Seung-Shin, Jung Sung-Hoon, Yang Deok-Hwan, Lee Je-Jung, Kim Nan Young, Choi Seung Hyun, Minden Mark D, Jung Chul Won, Jang Jun-Ho, Kim Hee Je, Moon Joon Ho, Sohn Sang Kyun, Won Jong-Ho, Kim Sung-Hyun, Kim Dennis Dong Hwan
Abstract excerpt
Normal karyotype acute myeloid leukemia (NK-AML) with CCAAT/enhancer binding protein α (CEBPA) mutations is known to have a more favorable prognosis. However, direct comparison of the clinical significance according to consolidation therapy has not been widely performed in patients with NK-AML. A total of 404 patients with NK-AML who received intensive induction chemotherapy were included in the present study....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
